Efficacy of the 7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline derivative against infection caused by Leishmania amazonensis
Rev. Soc. Bras. Med. Trop
; 53: e20200091, 2020. graf
Article
in En
| SES-SP, ColecionaSUS, LILACS
| ID: biblio-1136875
Responsible library:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
The drugs currently available for leishmaniasis treatment have major limitations.METHODS:
In vitro and in vivo studies were performed to evaluate the effect of a quinoline derivative, Hydraqui (7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline, against Leishmania amazonensis. In silico analyses of absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters were performed.RESULTS:
Hydraqui showed significant in vitro anti-amastigote activity. Also, Hydraqui-treated mice exhibited high efficacy in lesion size (48.3%) and parasitic load (93.8%) reduction, did not cause hepatic and renal toxicity, and showed appropriate ADMET properties.CONCLUSIONS:
Hydraqui presents a set of satisfactory criteria for its application as an antileishmanial agent.Key words
Full text:
1
Index:
LILACS
Main subject:
Quinolines
/
Leishmania mexicana
/
Leishmaniasis, Cutaneous
/
Antiprotozoal Agents
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Rev. Soc. Bras. Med. Trop
Journal subject:
MEDICINA TROPICAL
Year:
2020
Type:
Article